Abstract
GnRH agonists are the established treatment of precocious puberty caused by premature stimulation of gonadotropin secretion. It has been reported that after an initial stimulation (“flare-up”) they reduce LH secretion by desensitization of pituitary GnRH receptors. Little has been published about the use of GnRH antagonists such as cetrorelix to control the onset of puberty and whether they are potentially advantageous compared with GnRH agonists. We conducted two multigroup experiments (12 and 10 d, respectively) treating prepubertal/peripubertal female rats with either the GnRH agonist triptorelin or buserelin and compared them with rats treated with the GnRH antagonist cetrorelix and controls to assess the effects on pubertal progress and serum hormones. In the second experiment, the effects of buserelin and cetrorelix on gene expression of the GnRH receptor, LH-β, FSH-β, and the alpha subunit genes in the pituitary were also investigated. Cetrorelix, triptorelin, and buserelin retarded the onset of puberty as determined by delayed vaginal opening, lower ovarian weights, and lower serum estradiol levels. However, although LH and FSH levels were stimulated by both agonists, they were inhibited by cetrorelix. In the cetrorelix versus buserelin experiment, pituitary gene expression of the GnRH receptor and LH-β subunit were significantly lower in cetrorelix treated rats compared with controls whereas buserelin had little effect. Expression of FSH-β and alpha subunit were stimulated by buserelin but not by cetrorelix. Even though all three of these GnRH analogues inhibited gonadal development and delayed the onset of puberty , the GnRH agonists had stimulating and inhibiting effects on the pituitary-gonadal axis whereas cetrorelix exerted only inhibiting effects. We conclude from this female rat model that cetrorelix may offer advantages for a more controlled medical treatment of precocious puberty compared with GnRH agonist treatment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- GnRH:
-
gonadotropin-releasing hormone
- CET:
-
cetrorelix
- TRIP:
-
triptorelin
- BUS:
-
buserelin
- RT-PCR:
-
reverse transcriptase polymerase chain reaction
References
Wildt L, Marshall G, Knobil E 1980 Experimental induction of puberty in the infantile female rhesus monkey. Science 207: 1373–1375
Oostdijk W, Partsch CJ, Drop SLS, Sippell WG 1991 Long-term results with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Acta Paediatr Scand Suppl 372: 39–45
Pescovitz OH, Barnes KM, Cutler GB Jr 1991 Effect of deslorelin dose in the treatment of central precocious puberty. J Clin Endocrinol Metab 72: 60–64
Sippell WG, Partsch CJ, Hümmelink R, Lorenzen F 1991 Long-term therapy with delayed-action LHRH-agonist decapeptyl depot in girls with precocious puberty. Gynäkologe 24: 108–113
Plosker GL, Brogden RN 1994 Leuprorelin—a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 48: 930–967
Haviv F, Bush EN, Knittle J, Greer J 1998 LHRH antagonists. Pharm Biotechnol 11: 131–149
Felberbaum R, Diedrich K 1996 Klinischer Einsatz der GnRH-Analoga im Rahmen der Sterilitätstherapie: Agonisten und Antagonisten. Gynäkologe 29: 420–432
Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the LH-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 15: 526–531
Behre HM, Kliesch S, Pühse G, Reissmann T, Nieschlag E 1997 High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum LH, FSH, and testosterone in normal men. J Clin Endocrinol Metab 82: 1403–1408
Oliviennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R 1998 The use of GnRH antagonist (cetrorelix®) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13: 2411–2414
Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM 1997 Suppression of endogenous testosterone in young men increases serum levels of HDL subclass lipoprotein A-I and lipoprotein (a). J Clin Endocrinol Metab 82: 3367–3372
Lamharzi N, Schally AV, Koppan M 1998 LH-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 77: 185–192
Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M 1998 Efficacy and safety of LH-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 83: 3826–3831
Bokser L, Srkalovic G, Szepeshazi K, Schally AV 1991 Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of LH-releasing hormone (SB 75). Neuroendocrinology 54: 136–145
Morale MC, Batticane N, Bartoloni G, Guarcello V, Farinella Z, Galasso MG, Marchetti B 1991 Blockade of central and peripheral LH-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of the cell-mediated and humeral immune responses. Endocrinology 128: 1073–1985
Phillips A, Hahn DW, Mc Guire JL, Ritchie D, Capetola RJ, Bowers C, Folkers K 1988 Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 43: 883
Feleder C, Jarry H, Leonhardt S, Moguilevsky JA, Wuttke W 1996 Evidence to suggest that gonadotropin-releasing hormone inhibits its own secretion by affecting hypothalamic amino acid neurotransmitter release. Neuroendocrinology 64: 298–304
Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K 1996 Down-regulation of pituitary receptors for LH-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci U S A 93: 2398–2402
Seong JY, Jarry H, Kuhnemuth S, Leonhardt S, Wuttke W, Kim K 1995 Effect of GABAergic compounds on gonadotropin-releasing hormone receptor gene expression in the rat. Endocrinology 136: 2587–2593
Kaiser UB, Zhao D, Cardona GR, Chin WW 1992 Isolation and characterization of cDNAs encoding the rat pituitary gonadotropin-releasing hormone receptor. Biochem Biophys Res Commun 189: 1645–1652
Chin WW, Godine JE, Klein DR, Chang AS, Tan LK, Habener JF 1983 Nucleotide sequence of the cDNA encoding the precursor of the beta subunit of rat lutropin. Proc Natl Acad Sci U S A 80: 4649–4653
Kato Y, Ezashi T, Hirai T, Kato T 1990 Strain difference in nucleotide sequences of rat glycoprotein hormone subunit cDNAs and gene fragment. Zool Sci 7: 879–887
Godine JE, Chin WW, Habener JF 1982 Alpha subunit of rat pituitary glycoprotein hormones. J Biol Chem 257: 8368–8371
Kwekkeboom DJ, Lamberts SW, Blom JH, Schroeder FH, De Jong FH 1990 Prolonged treatment with the GnRH analogue buserelin does not affect alpha-subunit production by the pituitary gonadotroph. Clin Endocrinol Oxf 32: 443–451
Uemura T, Yanagisawa T, Shirasu K, Matsuyama A, Minaguchi H 1992 Mechanisms involved in the pituitary desensitization induced by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 167: 283–291
Jaakkola T, Ding YQ, Kellokumpu-Lehtinen P, Valavaara R, Martikainen H, Tapanainen J 1990 The ratios of serum bioactive/immunoreactive LH and FSH in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay. J Clin Endocrinol Metab 70: 1496–1505
Huhtaniemi IT, Warren DD, Catt KJ 1983 Comparison of oestrogen and GnRH agonist analogue-induced inhibition of the pituitary-testicular function in rat. Acta Endocrinol Copenh 103: 163–171
Hori H, Uemura T, Minaguchi H 1998 Effects of GnRH on protein kinase C activity, Ca2+ mobilization and steroidogenesis of human granulosa cells. Endocr J 45: 175–182
Lin Y, Kahn JA, Hillensjo T 1999 Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?. Hum Reprod 14: 885
Mori H, Ohkawa T, Takada S, Morita T, Yago N, Arakawa S, Okinaga S 1994 Effects of gonadotropin-releasing hormone agonist on steroidogenesis in the rat ovary. Horm Res 41: 14
Saragueta PE, Lanuza GM, Baranao JL 1997 Inhibitory effect of gonadotrophin-releasing hormone (GnRH) on rat granulosa cell DNA synthesis. Mol Reprod Dev 47: 170–174
Uemura T, Namiki T, Kimura A, Yanagisawa T, Minaguchi H 1994 Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans. Horm Res 41: 7
Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC 2000 Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141: 72–80
Yano T, Yano N, Matsumi H, Morita Y, Tsutsumi O, Schally AV, Taketani Y 1997 Effect of LH-releasing hormone analogs on the rat ovarian follicle development. Horm Res 48: 35
Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV 1996 Chronic administration of the LH-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor mRNA levels in rats. Endocrinology 137: 3430–3436
Acknowledgements
The authors thank Dr. Reissmann, ASTA Medica, Frankfurt, Germany, who kindly provided the drug cetrorelix acetate to us as a gift. We also thank M. Neff-Heinrich in editing this article, M. Metten for her kind support in the laboratory, and U. Munzel, Department of Medical Statistics, University of Göttingen, for statistical analysis of the data.
Author information
Authors and Affiliations
Additional information
Parts of the studies were supported by a DFG-grant (Ja 398 (6–1).This paper is part of the habilitation thesis of C. Roth.
Rights and permissions
About this article
Cite this article
Roth, C., Leonhardt, S., Seidel, C. et al. Comparative Analysis of Different Puberty Inhibiting Mechanisms of Two GnRH Agonists and the GnRH Antagonist Cetrorelix Using a Female Rat Model. Pediatr Res 48, 468–474 (2000). https://doi.org/10.1203/00006450-200010000-00009
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200010000-00009
This article is cited by
-
The ovarian reserve is depleted during puberty in a hormonally driven process dependent on the pro-apoptotic protein BMF
Cell Death & Disease (2017)
-
Hypothalamic Suppression Decreases Bone Strength Before and After Puberty in a Rat Model
Calcified Tissue International (2009)
-
A dose-response study on the estrogenic activity of benzophenone-2 on various endpoints in the serum, pituitary and uterus of female rats
Archives of Toxicology (2006)
